Luye Pharma’s Rykindo® approved by FDA for treatment of schizophrenia and bipolar 1 disorder

January 16, 2023
Research and Development

International pharmaceutical company, Luye Pharma, has announced that Rykindo® has received FDA approval for the treatment of schizophrenia in adult …

AstraZeneca’s Tezspire gains CHMP approval for the treatment of severe asthma

January 16, 2023
Research and Development

AstraZeneca has announced that Tezspire (also known as tezepelumab) has received approval from the EMA’s Committee for Medicinal Products for …

Poolbeg announces strategic expansion of POLB 001 into oncology

January 16, 2023
Business Services

16 January 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical …

finnCap Cavendish advises on the sale of MBI Healthcare Technologies to DNV

January 13, 2023
Business Services

London, 9th January – finnCap Cavendish, part of finnCap Group plc, is pleased to announce it has advised the three …

Pfizer’s COVID-19 vaccine under FDA’s examination following new research into adverse side effects

January 13, 2023
Medical Communications

The FDA, along with Taiwanese medical institutions, have been evaluating Pfizer’s mRNA COVID-19 vaccine, questioning the CDC’s omission of known …

Diabeloop and EOFlow team up to develop an automated insulin device

January 13, 2023
Medical Communications

Diabeloop, a medical device company focused on automated diabetes treatment solutions, and South Korea-based EOFlow have joined forces to offer …

First patient enrolled in Inari DEFIANCE trial for deep vein thrombosis

January 13, 2023
Research and Development

Inari Medical has announced that the first patient has been enrolled in the DEFIANCE trial. This trial will evaluate the …

MediciNova completes enrolment for phase 2 clinical trial of ibudilast to treat recurrent and newly diagnosed glioblastoma

January 13, 2023
Research and Development

Biopharmaceutical company MediciNova has announced that its phase 2 clinical trial to assess MN-166 (ibudilast) for the treatment of recurring …

Ajinomoto and Exelixis sign agreement to develop novel ADCs for cancer treatment

January 12, 2023
Research and Development

Ajinomoto Co., a Japanese biotech company providing biopharmaceuticals, has signed a license agreement with Exelixis Inc., an oncology-focused biotech company, …

BD showcase new-generation robotic track system for microbiology labs

January 12, 2023
Medical Communications

US-based Becton, Dickinson and Company (BD) has revealed new-generation robotic track system for its BD Kiestra microbiology laboratory solution which …

Oramed shares disappointing top-line results from phase 3 trial for type 2 diabetes treatment

January 12, 2023
Research and Development

Clinical stage pharmaceutical company, Oramed Pharmaceuticals, has announced top-line results from its phase 3 randomised, double-blind, placebo-controlled, multicentre trial, which …

Alvotech’s golimumab biosimilar phase 1 trial begins

January 12, 2023
Research and Development

Alvotech has announced that it has begun a phase 1 study evaluating the safety, tolerability and pharmacokinetics of its golimumab …

Avillion announces US approval of AstraZeneca’s Airsupra (PT027) as new rescue treatment for asthma

January 11, 2023
Business Services

London, UK, 11 January 2023 – Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical …

New technology to “unlock” NHS records to revolutionise how we take medicine

January 11, 2023
Business Services

London, UK – New technology which can “unlock” medication records has been awarded £1m in fresh funding by Innovate UK.

FDA clears first ACL reconstruction device for use in paediatric patients

January 11, 2023
Medical Communications

The FDA has cleared the ACL TightRope® II implant to treat torn knee ligaments in children and adolescents. The implant …

AbbVie and Anima collaborate for mRNA biology modulators

January 11, 2023
Research and Development

AbbVie and Amina Biotech have announced their collaboration for the discovery and development of mRNA biology modulators focusing on three …

FDA grants approval to third-generation VERO Biotech GENOSYL delivery system

January 11, 2023
Research and Development

The FDA has approved US-based medical equipment supplier VERO Biotech’s new-generation tankless inhaled nitric oxide (iNO) delivery system. This new …

BioNTech acquires AI company InstaDeep for £562m

January 11, 2023
Medical Communications

Germany-based BioNTech has acquired UK AI start up InstaDeep for £562m after a multi-year partnership. The acquisition is part of …

Insilico Medicine shares positive topline results of phase 1 trial of AI-designed drug for AI-discovered target

January 10, 2023
Medical Communications

Clinical stage AI-driven drug R&D company, Insilico Medicine, has announced positive topline results from its phase 1 trial assessing the …

The Gateway to Local Adoption Series

Latest content